Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Cash from Investing Activities (2016 - 2025)

Cytosorbents (CTSO) has disclosed Cash from Investing Activities for 14 consecutive years, with $55000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Investing Activities rose 118.39% year-over-year to $55000.0, compared with a TTM value of -$248430.0 through Sep 2025, up 63.52%, and an annual FY2024 reading of -$669430.0, up 28.5% over the prior year.
  • Cash from Investing Activities was $55000.0 for Q3 2025 at Cytosorbents, up from -$131758.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $140285.0 in Q2 2023 and bottomed at -$4.7 million in Q2 2022.
  • Average Cash from Investing Activities over 5 years is -$656131.7, with a median of -$257715.0 recorded in 2023.
  • The sharpest move saw Cash from Investing Activities plummeted 528.53% in 2021, then surged 118.39% in 2025.
  • Year by year, Cash from Investing Activities stood at -$1.7 million in 2021, then surged by 87.68% to -$206080.0 in 2022, then skyrocketed by 34.04% to -$135922.0 in 2023, then increased by 8.45% to -$124430.0 in 2024, then soared by 144.2% to $55000.0 in 2025.
  • Business Quant data shows Cash from Investing Activities for CTSO at $55000.0 in Q3 2025, -$131758.0 in Q2 2025, and -$47242.0 in Q1 2025.